Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.

Journal of gastroenterology and hepatology - 1 Sept 2021

Mou Haibo, Yang Qiu-An, Yu Lanfang, Wang Ting, Liu Kui, Shen Rong, Pan Xuedong, Dai Yi, Wan Qing, Zhou Fangling, Qian Lili, Chen Donglin, Yau Thomas, Dong Xiaowei, Wang Xuemei, Wang Shuang

Abstract excerpt

BACKGROUND AND AIM: Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti-PD1/PD-L1 therapy showed promising results. However, less is known about the PD-L1 immunohistochemistry score and factors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen

Share to Biomarkers, Tumor

Share to Carcinoma, Hepatocellular

Share to Immunochemistry

Share to Liver Neoplasms

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33656759
DOI: 10.1111/jgh.15475
PMCID: PMC8518358

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.PMID 33656759Read ↗

Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinomaSemantic proximity Read ↗

PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.Semantic proximity Read ↗

High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular featuresSemantic proximity Read ↗

The current status and future of PD-L1 in liver cancerSemantic proximity Read ↗

Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinomaSemantic proximity Read ↗

Programmed death-ligand 1 (PD-L1) polymorphisms as predictive biomarkers for the development of liver cirrhosis and hepatocellular carcinoma in HCV Egyptian patients.Semantic proximity Read ↗

Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression.Semantic proximity Read ↗

PDCL3 is a Novel Oncogenic Indicator in Hepatocellular Carcinoma using Comprehensive Bioinformatics Analysis and in vitro ValidationSemantic proximity Read ↗

Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.Semantic proximity Read ↗

Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.Semantic proximity Read ↗

Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.